NOVEL FORMULATION OF RECOMBINANT HUMAN ERYTHROPOIETIN NANOPARTICLES FOR SAFE AND EFFECTIVE RELEASE
Main Article Content
Abstract
Recombinant Human Erythropoietin (rHu-EPO) are the drugs which stimulates the bone marrow to produce red blood
cells in the body. rHu-EPO is used as erythropoietin stimulating agents in the treatment of renal and chemotherapy
induced anemia. rHu-EPO and its analogues currently available in the market is in parenteral dosage form which is
readymade injection preparation (syringe) which needs to be administered 2-3 times weekly to achieve the therapeutic
effect of parenterally administered rHu-EPO. These cumulative doses exceed the levels of endogenous Erythropoetin
(EPO) which may cause unspecific binding to non-targeted tissue and may lead to severe side effects. In this study we
incorporate rHu-EPO in polymeric nanoparticles which release rHu-EPO in systemic circulation for 14 days after single
dose of rHu-EPO nanoparticles. Produced nanoparticles were appeared in the range of 128.2±5.3 nm which was
spherical in shape and entrapped ~44% rHu-EPO. In-vitro release was ~62% within the first week and~81% up-to twoweek period. Biological activity performed on albino mice. Single 150 IU and 300 IU dose of rHu-EPO nanoparticles
preparation showed improvement in RBC and Hemoglobin rate up to 2 weeks and only up to 4 days after pure rHu-EPO
solution and marketed preparation (Eprex).
cells in the body. rHu-EPO is used as erythropoietin stimulating agents in the treatment of renal and chemotherapy
induced anemia. rHu-EPO and its analogues currently available in the market is in parenteral dosage form which is
readymade injection preparation (syringe) which needs to be administered 2-3 times weekly to achieve the therapeutic
effect of parenterally administered rHu-EPO. These cumulative doses exceed the levels of endogenous Erythropoetin
(EPO) which may cause unspecific binding to non-targeted tissue and may lead to severe side effects. In this study we
incorporate rHu-EPO in polymeric nanoparticles which release rHu-EPO in systemic circulation for 14 days after single
dose of rHu-EPO nanoparticles. Produced nanoparticles were appeared in the range of 128.2±5.3 nm which was
spherical in shape and entrapped ~44% rHu-EPO. In-vitro release was ~62% within the first week and~81% up-to twoweek period. Biological activity performed on albino mice. Single 150 IU and 300 IU dose of rHu-EPO nanoparticles
preparation showed improvement in RBC and Hemoglobin rate up to 2 weeks and only up to 4 days after pure rHu-EPO
solution and marketed preparation (Eprex).
Downloads
Download data is not yet available.
Article Details
How to Cite
Dhapake, P., & Avari, J. (2021). NOVEL FORMULATION OF RECOMBINANT HUMAN ERYTHROPOIETIN NANOPARTICLES FOR SAFE AND EFFECTIVE RELEASE. Journal of Advanced Scientific Research, 12(02 Suppl 1), 132-139. https://doi.org/10.55218/JASR.s12021122sup128
Section
Research Article
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.